Literature DB >> 16830242

[Palliative therapy in glioblastoma multiforme: a multimodal concept].

Viktoria Faber1, Ralf Thödtmann, Christine Marosi.   

Abstract

We report on a 72-year-old patient with a glioblastoma multiforme, who after initial operation underwent concomitant radiation (60 Gy) and chemotherapy (CCNU), which had to be stopped due to toxicity. After an interval without antineoplastic therapy lasting for several months, disease progressed. In this situation we decided to start second-line chemotherapy (Temozolomid). Because of cystic tumoural lesions an additional operative procedure was performed (Rickham reservoir). The latter had no major impact on quality of life for our patient. These procedures lead to an improvement of symptoms lasting for several months. Nevertheless our patient died 11 months after initial diagnosis due to a progression of the disease. This case report shows that multimodal therapeutic approaches should be taken into account in patients in a palliative situation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16830242     DOI: 10.1007/s10354-006-0285-6

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  12 in total

1.  Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group.

Authors:  W K Yung; M D Prados; R Yaya-Tur; S S Rosenfeld; M Brada; H S Friedman; R Albright; J Olson; S M Chang; A M O'Neill; A H Friedman; J Bruner; N Yue; M Dugan; S Zaknoen; V A Levin
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

2.  Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.

Authors:  Roger Stupp; Pierre-Yves Dietrich; Sandrine Ostermann Kraljevic; Alessia Pica; Ivan Maillard; Phillipe Maeder; Reto Meuli; Robert Janzer; Gianpaolo Pizzolato; Raymond Miralbell; François Porchet; Luca Regli; Nicolas de Tribolet; René O Mirimanoff; Serge Leyvraz
Journal:  J Clin Oncol       Date:  2002-03-01       Impact factor: 44.544

Review 3.  Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials.

Authors:  L A Stewart
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

4.  Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome.

Authors:  B C Devaux; J R O'Fallon; P J Kelly
Journal:  J Neurosurg       Date:  1993-05       Impact factor: 5.115

5.  Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults.

Authors:  H A Fine; K B Dear; J S Loeffler; P M Black; G P Canellos
Journal:  Cancer       Date:  1993-04-15       Impact factor: 6.860

6.  Morbidity and mortality of craniotomy for excision of supratentorial gliomas.

Authors:  C Fadul; J Wood; H Thaler; J Galicich; R H Patterson; J B Posner
Journal:  Neurology       Date:  1988-09       Impact factor: 9.910

7.  Treatment of recurrent high grade astrocytoma; results of a systematic review of 1,415 patients.

Authors:  M Huncharek; J Muscat
Journal:  Anticancer Res       Date:  1998 Mar-Apr       Impact factor: 2.480

8.  Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials.

Authors:  J R Simpson; J Horton; C Scott; W J Curran; P Rubin; J Fischbach; S Isaacson; M Rotman; S O Asbell; J S Nelson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1993-05-20       Impact factor: 7.038

Review 9.  Retreatment of intracranial gliomas.

Authors:  H J Landy; L Feun; J G Schwade; S Snodgrass; Y Lu; F Gutman
Journal:  South Med J       Date:  1994-02       Impact factor: 0.954

10.  The relationship between survival and the extent of the resection in patients with supratentorial malignant gliomas.

Authors:  M R Quigley; J C Maroon
Journal:  Neurosurgery       Date:  1991-09       Impact factor: 4.654

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.